Abstract
Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Graphical Abstract
Current Neuropharmacology
Title:The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia
Volume: 14 Issue: 5
Author(s): Carlo Maj, Alessandra Minelli, Edoardo Giacopuzzi, Emilio Sacchetti and Massimo Gennarelli
Affiliation:
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Abstract: Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Export Options
About this article
Cite this article as:
Maj Carlo, Minelli Alessandra, Giacopuzzi Edoardo, Sacchetti Emilio and Gennarelli Massimo, The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia, Current Neuropharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570159X13666150514232745
DOI https://dx.doi.org/10.2174/1570159X13666150514232745 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Comparison of Machine Learning Techniques Based Brain Source Localization Using EEG Signals
Current Medical Imaging Monoamino Oxidase A: An Interesting Pharmacological Target for the Development of Multi-Target QSAR
Mini-Reviews in Medicinal Chemistry The Interplay Between Depression and Parkinson´s Disease: Learning the Link Through Ca<sup>2+</sup>/cAMP Signaling
Current Protein & Peptide Science Genes, Blame and Loss of Control: is there a Place in Criminal Law for a ‘Genetic Defense’?
Recent Advances in DNA & Gene Sequences (Discontinued) Alzheimer’s Disease Brain Areas: The Machine Learning Support for Blind Localization
Current Alzheimer Research Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Development and Validation of 'Level A' In Vitro - In Vivo Correlation for Extended Release Tablets of Lamotrigine
Current Bioactive Compounds Design and Evaluation of Transdermal Patches of Timolol Maleate
Current Drug Delivery Probing an Artificial Polypeptide Receptor Library Using a Series of Novel Histamine H3 Receptor Ligands
Combinatorial Chemistry & High Throughput Screening Opportunities to Improve the Prevention and Treatment of Cervical Cancer
Current Molecular Medicine New Insight in Improving Therapeutic Efficacy of Antipsychotic Agents: An Overview of Improved In Vitro and In Vivo Performance, Efficacy Upgradation and Future Prospects
Current Drug Targets Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
Current Neuropharmacology Characterisation of Mitochondrial DNA Deletions by Long-PCR in Central Nervous System Regions of Young, Middle- and Old-aged Rats
Current Aging Science Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Novel Derivatives of Benfluron and Dimefluron Synthesis and Anticancer activity
Letters in Drug Design & Discovery Peptides as Modulators of α-Synuclein Aggregation
Protein & Peptide Letters Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets